Cargando…

Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease

Adalimumab is a monoclonal antibody used for inflammatory bowel disease. Due to its considerably variable pharmacokinetics, the loss of response and the development of anti-antibodies, it is highly recommended to use a model-informed precision dosing approach. The aim of this study is to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marquez-Megias, Silvia, Ramon-Lopez, Amelia, Más-Serrano, Patricio, Diaz-Gonzalez, Marcos, Candela-Boix, Maria Remedios, Nalda-Molina, Ricardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398570/ https://www.ncbi.nlm.nih.gov/pubmed/34452204 http://dx.doi.org/10.3390/pharmaceutics13081244

Ejemplares similares

Population Pharmacokinetic Model of Adalimumab Based on Prior Information Using Real World Data
por: Marquez-Megias, Silvia, et al.
Publicado: (2023)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Adalimumab in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2022)

Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011)

Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
por: Mocci, Giammarco, et al.
Publicado: (2022)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
por: Nuij, V. J. A. A., et al.
Publicado: (2017)

Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease
por: Lucafò, Marianna, et al.
Publicado: (2021)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
por: Goncalves, Joao, et al.
Publicado: (2019)

Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases
por: Elewaut, Dirk, et al.
Publicado: (2021)

Changes in Patient Reported Pain Measures With the Citrate-free Adalimumab Formulation in Pediatric Inflammatory Bowel Disease Patients
por: Patel, Ashish S., et al.
Publicado: (2020)

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
por: Imagawa, Tomoyuki, et al.
Publicado: (2012)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
por: Chang, Chen-Wang, et al.
Publicado: (2014)

T.06.4 LONG TERM EFFICACY AND SAFETY OF ABP 501 ADALIMUMAB BIOSIMILAR ON INFLAMMATORY BOWEL DIESASES: THE ADASWITCH STUDY
por: Cingolani, A., et al.
Publicado: (2022)

Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
por: Wang, Han, et al.
Publicado: (2022)

Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice
por: Calvo Moya, Marta, et al.
Publicado: (2023)

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
por: Nordfjeld, Kim, et al.
Publicado: (2012)

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
por: Lin, Wei-Chen, et al.
Publicado: (2017)

Novel technologies to characterize and engineer the microbiome in inflammatory bowel disease
por: Boix-Amorós, Alba, et al.
Publicado: (2022)

Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing
por: Neroutsos, Efthymios, et al.
Publicado: (2022)

The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review
por: Wiersma, Thomas K., et al.
Publicado: (2022)

Dose escalation of adalimumab as a strategy to overcome anti-drug antibodies: A case report of infantile-onset inflammatory bowel disease
por: Ancona, Silvana, et al.
Publicado: (2023)

Complete Regression of Giant Inflammatory Polyp after Treatment with Adalimumab
por: Abou Rached, Antoine, et al.
Publicado: (2019)

Extensive Nevus Comedonicus with Inflammatory Nodules and Cysts Controlled with Adalimumab
por: Lee, Eun Hye, et al.
Publicado: (2021)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers
por: Tursi, Antonio, et al.
Publicado: (2018)

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study
por: Shinzaki, Shinichiro, et al.
Publicado: (2021)

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
por: Toja-Camba, Francisco José, et al.
Publicado: (2023)

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis
por: Kobayashi, Shigeto, et al.
Publicado: (2011)

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
por: Kingsbury, Daniel J., et al.
Publicado: (2014)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
por: Hillson, Jan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_uklevbei9rsk2296ua57ogrsqq